Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sdcasper here is what I found so fare
this is on page f-35 link provided
On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. in exchange for 100,000,000 restricted MyDx common stock. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. The 45 days have expired and the parties continue to negotiate in good faith to consummate the transaction.
find more here source
https://ih.advfn.com/p.php?pid=nmona&article=74383982
this is on the bottom of page 26 link provided as source
Acquisition Agreement
On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. As of the date of this agreement, this transaction is on hold.
source
https://ih.advfn.com/p.php?pid=nmona&article=75488519
still looking but here is more
this is on the bottom of page 26 link provided as source
Acquisition Agreement
On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. As of the date of this agreement, this transaction is on hold.
source
https://ih.advfn.com/p.php?pid=nmona&article=75488519
On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. in exchange for 100,000,000 restricted MyDx common stock. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. The 45 days have expired and the parties continue to negotiate in good faith to consummate the transaction.
find more here source
https://ih.advfn.com/p.php?pid=nmona&article=74383982
I AM LOOKING FOR MORE ON THIS. I JUST HAPPEN TO COME ACROSS THIS ON A GOOGLE SEARCH
I read the whole thing, can someone give me the cliff notes?
RIGH SOMETHING OF INTEREST HERE TO LOOK AT
Acquisition Agreement
On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. The parties are still in the process of completing transaction documents.
Quarterly report pursuant to Section 13 or 15(d)
11. Commitments and Contingencies
On April 1, 2015, the Company signed a 31-month lease for approximately 6,200 square feet of office and laboratory space at 6335 Ferris Square, Suite B, San Diego, California. The facility includes approximately 1,500 square feet of laboratory space. Commencement date of the lease is May 1, 2015. Total net rent under this lease is $247,000 and expires on November 30, 2017.
The annual minimum lease payments under non-cancellable operating leases, including common area maintenance and amortization of leasehold improvements that have an initial or remaining term in excess of one year at March 31, 2017 are due as follows:
2017 63,134
Total minimum lease payments $ 63,134
Rent expense for the three months ended March 31, 2017 and 2016 was $18,479 and $32,073, respectively.
On April 21, 2016, the Company subleased a portion of the facility to an unrelated third party on a month-to-month basis commencing May 1, 2016. Monthly gross rent from the subtenant is $5,000 per month. Subtenant must provide the Company with ninety days prior written notice of its intent to terminate the sublease.
Distribution and License Agreement and Joint Development Agreements
The Company entered into a Distribution and License Agreement with a third-party for the purpose of developing a sensor array to be used in the Company’s product. The Distribution and License Agreement has an initial term of ten years, but can be terminated earlier if the project does not meet the specifications of the Company. The Company will obtain exclusive rights to sell and distribute once a successful sensor prototype is developed. In exchange for a functional prototype, the Company will pay the third-party a 7% royalty on net sales. During the three months ended March 31, 2017 and 2016, the Company did not incur any development costs related to the Distribution and License Agreement.
On November 1, 2013, the Company entered into a two-year Joint Development Agreement (the “Agreement”) with an unrelated third-party to develop chemical sensors and peripheral sensing equipment and software for the detection and characterization of cannabis and compounds associated with cannabis.
The Agreement provides for, among other things, any arising intellectual property rights (as defined) outside of the field (as defined), and any arising intellectual property rights relating to improvements to detection materials shall belong to the Joint Venture Developer.
The Agreement also provides that any arising intellectual property rights other than those covered above shall belong to the Company. To the extent that it is necessary to do so to enable the Company to use and exploit its respective arising intellectual property rights, the Joint Developer grants the Company a perpetual, irrevocable, exclusive, and royalty free license (including the right to assign the license and to grant sub-licenses) to use and exploit the Joint Developer’s arising intellectual property rights in the field. Under the terms of the Agreement, either party may cancel the Agreement as the specific tasks provided for in the Agreement have been completed or for causes specifically provided for in the Agreement. During the years ended December 31, 2015 and 2014, the Company paid the Joint Developer $200,000 and $227,500 for development costs, respectively.
On May 19, 2015, the Company entered into an Exclusive Patent Sublicense Agreement (the “License Agreement”) with Next Dimension Technologies, Inc. (“NDT”). The License Agreement grants the Company a worldwide right to the patents licensed by NDT from the California Institute of Technology. The License Agreement grants both exclusive and non-exclusive patent rights. The license granted in the License Agreement permits the Company to make, have made, use, sell and offer for sale sublicensed products in the field of use. The License Agreement continues until the expiration, revocation, invalidation or enforceability of the rights licensed. The License Agreement provides for the payment of a license fee and royalty payments by CDx to NDT. The License Agreement also contains minimum royalty payments and milestone payments by CDx to NDT. NDT has a right to terminate the License Agreement in the event of an uncured breach by CDx; the insolvency or bankruptcy of CDx; or if CDx does not meet certain productivity milestones. The License Agreement also contains representations, warranties and indemnity obligations for each of CDx and NDT. In connection with the License Agreement, on May 19, 2015, CDx and NDT also executed an Amended Amendment No. 4 (the “Amended Amendment No. 4”) to the Joint Development Agreement, dated as of November 1, 2013, between CDx and NDT, which extended the date of negotiation for the License Agreement through May 19, 2015.
On February 8, 2017, MyDx, Inc. entered into an option agreement (the “Option Agreement’) with the Torque Research & Development, Inc. (“TRD”). The Option Agreement provides MyDx with the exclusive right to license two patent pending inventions (the “TRD Inventions”), and requires MyDx to make annual payments to TRD as well as royalty payments on any products that are commercialized which are based on the TRD Inventions. MyDx’s rights under the Option Agreement require customary measures of performance on the part of MyDx in terms of patent cost maintenance and other payments of costs associated with the TRD Inventions. With respect to the Option Agreement, MyDx rights are broad in terms of the potential access MyDx has to use the TRD Inventions in products, and services and many of the key economic terms of a future license, should MyDx exercise its rights under the Option Agreement, are agreed to in the Option Agreement.
In addition to the Option Agreement with the TRD, on February 8, 2017, MyDx has entered into a research and development agreement (the “RD Agreement”) with TRD for the Project titled “Manufacturable, Medical Grade Smart Vape Devices and Related Medical Software Applications for Prescribers, Administrators and Patient Applications.” The RD Agreement allows MyDx to fund research based on the TRD Inventions with a three year budget of $280,371 and a deferred payment of $75,000 within ninety days of the Effective Date. The RD Agreement provides MyDx with an exclusive right to license all technology that is discovered from the monies funded to TRD through the RD Agreement (the “Derivative IP”). To the extent that MyDx exercises its rights under the RD Agreement, MyDx will be required to make customary annual payments to TRD, who shall be the owners of any Derivative IP, as well as royalty payments as any commercialization of such Derivative IP occurs. TRD may elect to accept payment in whole or in part in cash or the companies restricted common stock priced at the Effective Date.
License and Distribution Agreement
On September 1, 2016, MyDx, Inc. (the “Company” or “Licensor”) entered into a Distribution and License Agreement (the “License Agreement”) with Powerfull Holdings, Ltd, a company operating under the charter of the People’s Republic of China (“Assignor”) and China Science and Technology, a Powerfull Holdings affiliated Company (“Licensee”), (together the “Parties”). The Parties intend there to be two phases of the License Agreement: Phase One and Phase Two. During Phase One, the Licensor shall provide test samples and validation data for market validation. Subject to Phase One producing satisfactory results, and proof of concept, the Parties will commence Phase Two.
For Phase One, the Licensee will pay the Licensor a minimum of Forty-Five Thousand Dollars ($45,000.00) as a Licensing and Technology Transfer Fee (the “Transfer Fee”) per application (AquaDx™, OrganaDx™, AeroDx™). These fees shall be credited towards Phase Two’s mandatory minimum payments. The Licensee shall pay the Transfer Fee within 10 business days of being provided with an invoice by the Licensor. However, should the Parties determine that the results of the activities of Phase One were not satisfactory to both parties, this Agreement shall terminate pursuant to Section 7.2(b).
In connection with the agreement referenced above, the licensor and licensee are currently still operating under Phase I and the company has not yet received adequate information to enter Phase II. MyDx has not yet received and has requested market feasibility, regulatory and other studies from Licensee as contemplated under the agreement and has requested the results of their Phase I findings to be delivered to Company on or before April 21, 2017. To the extent MyDx management is unable to receive satisfactory results and confirm proof of concept, MyDx has notified Licensee it will be difficult to continue under the current agreement and the parties are permitted to terminate for cause and defectiveness in the event the products do not pass tests for quality, reliability, efficacy, and marketability or if at the completion of Phase I, the results were not satisfactory and the concept was not proven.
Marketing and Advertising Advisory Services Agreement
On April 5, 2016, the Company entered into a Marketing and Advertising Advisory Services Agreement (the “Agreement”) with Growth Point Advisors, Ltd. (“Growth Point”) for Growth Point to provide a comprehensive marketing, advertising and branding campaign for the Greater China Region on behalf of the Company’s MyDx AquaDx sensor. The campaign shall include, but not be limited to, the development of both the front and back-end of an e-commerce web site targeting the Chinese audience as well as introductions to potential key personnel to launch and manage the campaign.
In consideration for the services described above, the Company shall pay Growth Point a monthly service fee of $30,000. Should the Company fail to pay the monthly service fee, Growth Point shall have the right to convert the monthly service fee into the Company’s common stock at a 50% discount of the lowest closing price of the Company’s common stock for the 15 trading days upon send notice of non-payment to the Company.
MyDx has disputed the balance of invoice due to Growth Point and has subsequently terminated this agreement.
On February 17, 2017 MyDx and Libre Design, LLC (“LDL”) entered into a twelve (12) month Research, Branding, Advertising and Marketing Services Agreement (“Agency Agreement”). The Company agreed to pay deferred cash compensation as follows of three thousand dollars ($3,000) upon execution and one thousand five hundred dollars ($1,500) per month for a subsequent eleven (11) payments thereafter on or before the first (1st) of each month. In addition, Agency is entitled to receive sixty seven million shares of restricted common stock at a closing market price equal to .0011.
On March 1 and 15th, 2017, MyDx, Inc. received a payment demand for the initial and subsequent payment of $50,000 and $25,000 per month respectively, exclusive of costs and other fees, due and owing under the BCI Advisors, LLC (“BCI”) advisory services agreement (the “Advisory Services Agreement”). The Company elected in lieu of cash to pay in unrestricted common stock, registered in form S-8. The Company made an initial payment of seventy five million shares in partial satisfaction of the amount due and owing that does not exceed the Company’s obligations under the Advisory Services Agreement to restrict BCI’s beneficial ownership to 4.99%. This summary contains only a brief description of the material terms of the Advisory Services Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such description is qualified in its entirety by reference to the Advisory Services Agreement. A copy of the Advisory Services Agreement was filed in a Current Report on Form 8-K.
Resale Licensing Agreement
On October 4, 2016, the Company executed a Resale Licensing Agreement with ANP Technologies, Inc. (“ANP”) (the “Agreement”) that outlines the terms and conditions for a One-Time, Non-Exclusive Resale License to MyDx, Inc. for the sale of ANP’s ACE-III-C pesticide and toxic heavy metal Lateral Flow Assay detection test under MyDx, Inc.’s brand. The Agreement provides for the purchase and resale of 10,000 units as part of a Phase I validation of the product’s merchantability.
Acquisition Agreement
On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. The parties are still in the process of completing transaction documents.
Litigation
In the normal course of business, the Company may be subject to other legal proceedings, lawsuits and other claims. Although the ultimate aggregate amount of probable monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, the Company’s management believes that any monetary liability or financial impact to the Company from these other matters, individually and in the aggregate, would not be material to the Company’s financial condition, results of operations or cash flows.
However, there can be no assurance with respect to such result, and monetary liability or financial impact to the Company from these other matters could differ materially from those projected.
SOURCE
http://ir.cdxlife.com/all-sec-filings/xbrl_doc_only/1100
Maybe there's no cash in testing. Maybe it's easier for Tina to open a certified lab, then take over the current one or certify it to code. Maybe Angel has been working other angles? Who knows but Angel and Tina.
Stanz lab hasn't had a new strain test in a month. Growth has stalled I guess.
http://budgenius.com/strains.html
Did Tina get all of his business or something? LOL
Long RIGH
Good volume. Any news on Tina's lab?
Must be a whale LOL
Long RIGH
What is a grey trade ???
2000000 gray trade. Loving it!
20 shares and we double yesterday's volume, % wise that's pretty good.
That's about the speed we are going
Lol, we're going to kill it 10 shares at a time!
No backing up here we are going forward!
Don't all back up the truck at once LOL ;)
Long RIGH
That's a thought
Maybe Tina will take her lab public and we can invest in her. ExGFLabGenius. EGLG.
Yes if we could just keep up this momentum
"Billions and billions and billions and billions and billions"
Long RIGH
You guys see BCrAP volume
Lol. I was kidding. You of all people would know if there is one.
LOL!! Sarcasm!!!!!!
Angel had a conference call? Any updates?
Great volume day guys. Woo hoo. Loved Angel's conference call earlier today. Good stuff.
Good luck to you
I've seen a bunch run here and there only to fall back. Corrupt CEO'S in the end. Unfortunately this one dropped to rock bottom. I wish Angel would tell us it's over or is all part of a master plan. Maybe Tina's lab is part of it. Who knows. I always felt there were forced holding Angel back. For example why are we still RightSmile? I still look everyday for some reason..
I do have to admit that I put a lot of dreams, (and cash) into this play. I bought into Stanz as well in the beginning. I just fell out sooner. I admire your commitment to this. You hung in there a long time, and took my crap in the process. I think marijuana is the way the truth, and the light to a payday of some kind. I just have to figure out what are viable options. I believe time is running short to really get in at the bottom of this. Any comments??
I have nothing for ya, we all know how disappointing its been.
How shocking can it possibly be when its been ages since upstanding business man Stanz has even bothered to fart in your direction?? Do tell.
No one responded to your email. Guess we are all in shock.
Wow, that's a lot of changes. I hope Angel keeps his loyal peeps in his plans.
I had some email communication about 6 weeks ago when I learned of Urban Laboratories.
I don't think Tina's move means anything negative about BG. Angel is the only board member of this new company.
https://angel.co/urban-labs
Luis quit BG earlier this year, but didn't go far landing at Charter Financial Group, one of Angel's private endeavors.
Tina's move seems more about her capitalizing on a private opportunity in the cannabis/testing environment.
I was frustrated to learn of this opportunity, I would hope that new ideas would be part of BG, not developed privately. Perhaps this was the only option to get friendly capital and may turn into a BG opportunity at a later date.
Either or, I didn't bring it up here. I had asked that a formal shareholder update be made to avoid speculation.
The girlfriend moving on its a telling sign. This is not good peeps. Vapes, any contact?
Funny you mention crypto currencies! One of my weed stocks just went crypto!
They are called Troptions...however, the stock STBV got suspended by the SEC after a 6,000% run and now it's on the greys :(.
Wish me luck!
Anybody hear from stanz? No tweets since June...no strain updates in over a month?
Long RIGH$
You are right about the cripto I have a little would like to get more
Maybe Angel is an executive producer of the new Netflix show "Disjointed"genius.
I wish I could take my total investment here and put it into crypto currencies.
I didn't hear the fat lady sing yet.
Trying to stay positive about this position .no tests in over a month on their website.
I saw your links. Apparently she is a LinkedIn connection to one of my good friends. Funny.
Hmmm... Guess Tina Urban quit Budgenius, though...
https://www.levo.com/tina-urban
At least Tina Urban is keeping busy...
Remember Tina? RIGH CEO Angel Stanz's girlfriend and supposed Director of Operations at BudGenius?
She's keeping busy, even if Angel has gone to ground.
Here ya go...
https://www.levo.com/tina-urban
https://www.linkedin.com/in/urbaniszt/
https://www.quora.com/profile/Tina-Urban-1
http://urbanlaboratories.io/
https://www.facebook.com/christina.urban.9822
Should be good for some buzz&rumors, no?
Someone has to do DD around here!
Anyone know why all the volume is gray?
Followers
|
660
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
92702
|
Created
|
11/07/08
|
Type
|
Free
|
Moderators |
RIGH should have been de-listed.
Bud Genius, Inc - RIGH
WARNING: BudGenius
was Administratively Dissolved
in its State of Incorporation, Wyoming, on 11/09/2015:
https://wyobiz.wy.gov/business/FilingDetails.aspx?eFNum=166014021188212044170002186232076063134194253191
Share Structure as of 2016-01-08:
http://www.otcmarkets.com/stock/RIGH/profile
Additionally, RIGH CEO Angel Stanz owns Convertible Preferred shares,
convertible to over 35 BILLION common shares at his discretion.
_______________________________
WARNING: The Transfer Agent (below) is gagged as per RIGH's instructions.
No share information is being released to the public.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |